A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product

Karina Juhl Rasmussen, Mikkel-Ole Skjødt, Lars Vitved, Karsten Skjoedt, Yaseelan Palarasah

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The complement component C3 and the cleavage products of C3b/iC3b, C3c and C3d are used as biomarkers in clinical diagnostics. Currently, no specific antibodies are able to differentiate C3d from other fragments, although such a distinction could be very valuable considering that they may reflect different pathophysiological mechanisms. We have developed a rat antihuman C3d monoclonal antibody with specificity to the end sequence of the N-terminal region of C3d. The antibody can therefore only bind to C3d when it manifests itself as the final end product of cleaved C3. We believe that this specificity is it first of its kind, and predicts that it can be used as a detection tool in several immunological methods with great value in diagnostics.

Original languageEnglish
JournalJournal of Immunological Methods
Volume444
Pages (from-to)51-55
ISSN0022-1759
DOIs
Publication statusPublished - May 2017

Keywords

  • C3d
  • Clinical diagnostic
  • End specificity
  • Monoclonal antibody
  • Antibody Specificity
  • Immunization
  • Complement Activation
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Rats, Sprague-Dawley
  • Animals
  • Injections, Subcutaneous
  • Protein Binding
  • Protein Interaction Domains and Motifs
  • Binding Sites, Antibody
  • Complement C3d/administration & dosage
  • Antibodies, Monoclonal/biosynthesis

Fingerprint

Dive into the research topics of 'A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product'. Together they form a unique fingerprint.

Cite this